← All drugs Report issue

gen1047

mAbexperimentalBi-specific

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

1

Phase 3

0

Phase 4

0

Earliest trial started Dec 13, 2021 (NCT05180474)

Timeline

2020s

Jan 1, 2021
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

T-cell surface glycoprotein CD3 epsilon chainAGONIST
CD3E
- T-cell surface glycoprotein CD3 epsilon chain (CD3E) ↗
V-set domain-containing T-cell activation inhibitor 1BINDING AGENT
B7H4
- V-set domain-containing T-cell activation inhibitor 1 (VTCN1) ↗

Chemistry & pharmacology

Multi-specific: Yes (Bi-specific)

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05180474	Phase 1/Phase 2 (Phase 2)	Dec 13, 2021	Genmab

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Genmab	For profit	1	1	1	2021

1 organizations

Page 1 / 1